Codexis Inc (CDXS) Reports Fiscal Year 2023 Financial Results [Yahoo! Finance]
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: Yahoo! Finance
Product Revenues : $42.9 million for FY 2023, including PAXLOVID enzyme sales, down from $116.7 million in FY 2022. R&D Revenues : Increased to $27.2 million in FY 2023 from $21.9 million in FY 2022. Net Loss : Reported at $76.2 million for FY 2023, widening from a net loss of $33.6 million in FY 2022. Product Gross Margin : Improved to 63% in FY 2023, up from 52% in FY 2022, excluding PAXLOVID enzyme sales. Cash Position : Approximately $70.1 million in pro forma cash and cash equivalents as of December 31, 2023. 2024 Guidance : Product revenues expected to be between $38 million to $42 million, excluding PAXLOVID revenue. Warning! GuruFocus has detected 6 Warning Signs with CDXS. On February 28, 2024, Codexis Inc ( NASDAQ:CDXS ), a prominent enzyme engineering firm, disclosed its financial outcomes for the fourth quarter and the fiscal year ending December 31, 2023. The company's 8-K filing revealed a mix of advancements and challenges as it navigates the evolving bio
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Codexis GAAP EPS of -$0.16 beats by $0.02, revenue of $17.1M beats by $3.8M [Seeking Alpha]Seeking Alpha
- Codexis Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Codexis Reports First Quarter 2024 Financial ResultsGlobeNewswire
- With 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- Codexis to Report First Quarter 2024 Financial Results on May 2GlobeNewswire
CDXS
Earnings
- 5/2/24 - Beat
CDXS
Sec Filings
- 5/2/24 - Form S-3
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- CDXS's page on the SEC website